New blood test uses nanotechnology to predict prostate cancer

From an article by Niamh Marriott:

The test, developed by Alberta scientists, incorporates a unique nanotechnology platform to make the diagnostic using only a single drop of blood, and is significantly more accurate than current screening methods.

The Extracellular Vesicle Fingerprint Predictive Score (EV-FPS) test uses machine learning to combine information from millions of cancer cell nanoparticles in the blood to recognise the unique fingerprint of aggressive prostate cancer.

The diagnostic, developed by members of the Alberta Prostate Cancer Research Initiative (APCaRI), was evaluated in a group of 377 Albertan men who were referred to their urologist with suspected prostate cancer. It was found that EV-FPS correctly identified men with aggressive prostate cancer 40% more accurately than the most common test – Prostate-Specific Antigen (PSA) blood test – in wide use today.

 

Read more
 timthumb.php_

Image Credit:   DTR

timthumb.php_

Recent News

NanoApps Medical Near-Term Projects

NanoApps Medical is investigating the possibility that superparamagnetic nanoparticles (SPIONs) and other classes of nanoparticles (e.g., gold coated nanoshells) might have the capacity to target cancerous tumors, metastasizing cancer [...]

 

2018-03-22T14:33:19+00:00

Leave A Comment